34.26 USD
+0.63 (+1.87%)
34.7799 USD
+0.52 (+1.52%)
We assign a fundamental rating of 7 out of 10 to GMAB. GMAB was compared to 530 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make GMAB suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year GMAB was profitable.
In the past year GMAB had a positive cash flow from operations.
GMAB had positive earnings in each of the past 5 years.
In the past 5 years GMAB always reported a positive cash flow from operatings.
1.2 Ratios
GMAB has a Return On Assets of 21.10%. This is amongst the best in the industry. GMAB outperforms 97.36% of its industry peers.
The Return On Equity of GMAB (25.76%) is better than 97.17% of its industry peers.
With an excellent Return On Invested Capital value of 17.11%, GMAB belongs to the best of the industry, outperforming 96.79% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GMAB is below the industry average of 18.28%.
The 3 year average ROIC (15.20%) for GMAB is below the current ROIC(17.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
GMAB has a Profit Margin of 41.35%. This is amongst the best in the industry. GMAB outperforms 97.17% of its industry peers.
In the last couple of years the Profit Margin of GMAB has declined.
The Operating Margin of GMAB (36.85%) is better than 97.74% of its industry peers.
GMAB's Operating Margin has declined in the last couple of years.
GMAB's Gross Margin of 94.27% is amongst the best of the industry. GMAB outperforms 94.91% of its industry peers.
GMAB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GMAB is creating value.
The number of shares outstanding for GMAB has been reduced compared to 1 year ago.
GMAB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, GMAB has a worse debt to assets ratio.
2.2 Solvency
GMAB has an Altman-Z score of 12.36. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of GMAB (12.36) is better than 84.34% of its industry peers.
The Debt to FCF ratio of GMAB is 0.12, which is an excellent value as it means it would take GMAB, only 0.12 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.12, GMAB belongs to the top of the industry, outperforming 95.85% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
The Debt to Equity ratio of GMAB (0.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 12.36 |
ROIC/WACC2.45
WACC6.99%
2.3 Liquidity
A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.03, GMAB is in the better half of the industry, outperforming 63.02% of the companies in the same industry.
A Quick Ratio of 6.01 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Quick ratio of 6.01. This is in the better half of the industry: GMAB outperforms 63.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
GMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.90%, which is quite impressive.
Measured over the past years, GMAB shows a very strong growth in Earnings Per Share. The EPS has been growing by 28.38% on average per year.
Looking at the last year, GMAB shows a very strong growth in Revenue. The Revenue has grown by 24.66%.
GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.16% yearly.
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
Based on estimates for the next years, GMAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.79% on average per year.
The Revenue is expected to grow by 13.32% on average over the next years. This is quite good.
EPS Next Y2.82%
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
EPS Next 5Y9.79%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.32%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 14.52, GMAB is valued correctly.
Based on the Price/Earnings ratio, GMAB is valued cheaply inside the industry as 96.60% of the companies are valued more expensively.
GMAB's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.19.
The Price/Forward Earnings ratio is 19.43, which indicates a rather expensive current valuation of GMAB.
GMAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 94.34% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.88, GMAB is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.52 | ||
| Fwd PE | 19.43 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaper than 96.60% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 96.23% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.53 | ||
| EV/EBITDA | 11.39 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of GMAB may justify a higher PE ratio.
PEG (NY)5.15
PEG (5Y)0.51
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
5. Dividend
5.1 Amount
GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
34.26
+0.63 (+1.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap21.10B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts71.85
Price Target38.24 (11.62%)
Short Float %1.95%
Short Ratio6.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.82%
EPS NQ rev (3m)5.19%
EPS NY rev (1m)0.04%
EPS NY rev (3m)4.69%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.52 | ||
| Fwd PE | 19.43 | ||
| P/S | 5.89 | ||
| P/FCF | 17.53 | ||
| P/OCF | 16.56 | ||
| P/B | 3.67 | ||
| P/tB | 5.79 | ||
| EV/EBITDA | 11.39 |
EPS(TTM)2.36
EY6.89%
EPS(NY)1.76
Fwd EY5.15%
FCF(TTM)1.95
FCFY5.7%
OCF(TTM)2.07
OCFY6.04%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)5.15
PEG (5Y)0.51
Graham Number22.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 12.36 |
F-Score7
WACC6.99%
ROIC/WACC2.45
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y2.82%
EPS Next 2Y-0.05%
EPS Next 3Y7.32%
EPS Next 5Y9.79%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.32%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y18.11%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
What is the valuation status for GMAB stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for GMAB stock?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 14.52 and the Price/Book (PB) ratio is 3.67.
Can you provide the financial health for GMAB stock?
The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.